Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Cambridge Cognition to join the Brain Health Registry as cognitive assessment partner

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it will be joining the University of California, San Francisco (UCSF) Brain Health Registry as a cognitive assessment partner. The Brain Health Registry is an online platform designed to speed up the discovery of treatments for Alzheimer's disease, Parkinson's disease, depression, post-traumatic stress disorder, and other brain disorders.

One of the key barriers facing treatment development for neurological and psychiatric conditions is difficulty recruiting the right patients into clinical trials and identifying these individuals at the very early stages of disease progression. In efforts to address this issue researchers at UCSF established the Brain Health Registry: an online enrolment platform for adults who are interested in participating in brain research.

Adults aged 18+ years who are interested in participating in research studies can enrol in the Brain Health Registry through the website: https://my.brainhealthregistry.org/BHR/register. This secure, online platform is then used to deliver baseline questions on health, lifestyle and medical history. To build a full and sustained picture of function over an individual's lifespan, participants are also asked to complete web-based questionnaires and cognitive assessments every 6 months: including the CANTAB^TM Paired Associates Learning task.

By regularly assessing healthy adults the Brain Health Registry is building a unique and important resource on functional change over time. This data will be used to identify potential candidates for clinical trials and establish novel biomarkers to detect early stages of brain disorders. This could be beneficial for Cambridge Cognition in providing more real-world data on the use of the assessment and potentially a cohort of patients already assessed with a CANTAB™ test that could be used for a clinical trial.

For further information on the Brain Health Registry visit https://www.brainhealthregistry.org/

Prof Michael Weiner, Lead Scientific Investigator at the Brain Health Registry, said:

"Accurate cognitive assessment is essential for the online Brain Health Registry to achieve its intended purpose: speeding up the discovery of effective treatments for brain disorders. Cambridge Cognition is joining us as a cognitive assessment partner helping us to speed up the discovery of effective treatments for brain disorders with their validated computerized cognitive assessments."  

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"One of the key challenges facing drug development is identifying which patients are most likely to benefit from a therapeutic intervention. The Brain Health Registry set up a web-based solution to tackle this issue: an online platform to longitudinally monitor adults who are interested in participating in research. The goal of our partnership is to assist the Brain Health Registry in bringing effective treatments for brain disorders by using our cognitive assessments." 

For further information, contact:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com